Earlier quoted context omitted.
The vaccines delivered to Brazil also have a replication deficient Ad5 vector, Anvisa says that among the vast majority of replication deficient vectors some replication-able viruses were present. There is pretty much no chance at all that this affects efficacy.
> Anvisa says that among the vast majority of replication deficient vectors some replication-able viruses were present. Do you have the source for this claim? Linked Anvisa slides page 6 says "todos os lotes" (all lots) had replicating virus. I agree this is about quality control and it is extremely unlikely to affect vaccine efficacy. (If anything, it would improve vaccine efficacy.)
Replicant viruses do not carry the spike protein, they don't contribute to antigen protection.